Real-world clinical outcomes, prognostic factors, and safety profile of upadacitinib in patients with inflammatory bowel disease

Figure 2 One-year efficacy outcomes of upadacitinib in patients with ulcerative colitis and Crohn’s disease. Dark blue bars represent the proportion of patients achieving each outcome, with exact patient numbers indicated at the base of each bar. Patients with ulcerative colitis achieved numerically higher rates compared to patients with Crohn’s disease. A: One-year clinical remission rates; B: One-year corticosteroid-free clinical remission rates; C: Endoscopic remission rates. UC: Ulcerative colitis; CD: Crohn’s disease.